SpectraScience (SpectraScience) ROCE % : 0.00% (As of Sep. 2017)

View and export this data going back to . Start your Free Trial

What is SpectraScience ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SpectraScience's annualized ROCE % for the quarter that ended in Sep. 2017 was 0.00%.

SpectraScience ROCE % Historical Data

The historical data trend for SpectraScience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpectraScience ROCE % Chart

SpectraScience Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

ROCE %

Get a 7-Day Free Trial

-1,894.29

SpectraScience Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

SpectraScience ROCE % Calculation

SpectraScience's annualized ROCE % for the fiscal year that ended in Dec. 2016 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2016 )		(A: Dec. 2015 )		(A: Dec. 2016 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2016 )		(A: Dec. 2015 )		(A: Dec. 2016 )
	=	-3.503	/	( ( (1.867 - 8.855)	+	(1.386 - 10.802) )	/ 2 )
	=	-3.503	/	( (-6.988	+	-9.416)	/ 2 )
	=	-3.503	/	-8.202
	=	42.71 %

SpectraScience's ROCE % of for the quarter that ended in Sep. 2017 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2017 )		(Q: Jun. 2017 )		(Q: Sep. 2017 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2017 )		(Q: Jun. 2017 )		(Q: Sep. 2017 )
	=	-3.744	/	( ( (1.234 - 11.952)	+	(1.218 - 12.805) )	/ 2 )
	=	-3.744	/	( ( -10.718	+	-11.587 )	/ 2 )
	=	-3.744	/	-11.1525
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2017) EBIT data.

SpectraScience (GREY:SCIE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SpectraScience ROCE % Related Terms

Thank you for viewing the detailed overview of SpectraScience's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

SpectraScience (SpectraScience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SpectraScience Inc (GREY:SCIE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11568-11 Sorrento Valley Road, San Diego, CA, USA, 92121

Website

http://www.spectrascience.com

SpectraScience Inc is a US based company focused on developing the WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The firm has developed a technology platform to determine if the tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT operates by using cool, safe UV laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin treatment during the same procedure. The group sells its product in the United States and Europe, of which majority of the sales revenue is derived from the United States.

Executives

Lowell Giffhorn	officer: CFO	10875 KEMAH LANE, SAN DIEGO CA 92131
John Pappajohn	director	1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
Euclidsr Partners, L.p.	10 percent owner	45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Euclidsr Associates, L.p.	10 percent owner	45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105

SpectraScience (SpectraScience) Headlines

No Headlines